Ever-increasing evidence has demonstrated the presence of upregulated Gal-3 in COVID-19 patients as compared with healthy controls (De Biasi et al., 2020; Tian et al., 2020), which underline the pro-inflammatory activity of Gal-3 in the progression of COVID-19 conditions. The gene discussed is LGALS3; the disease is COVID-19.